Ara
Toplam kayıt 12, listelenen: 1-10
Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study
(Taylor & Francis Inc, 2022)
Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) ...
Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer
(Lippincott Williams & Wilkins, 2021)
The aim of this study was to investigate the predictive and prognostic value of PLR, and the relationship between PLR and tumor localization. A total of 229 patients with de-novo metastatic CRC were retrospectively analyzed. ...
Prognostic significance of metastatic lymph node ratio in patients with pN3 gastric cancer who underwent curative gastrectom
(Karger, 2019)
Background: Lymph node involvement is an important prognostic factor in patients with gastric cancer. The aim of this study was to determine the prognostic significance of metastatic lymph node ratio (MLNR) and compare it ...
Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: Single center experience from Turkey
(Lippincott Williams and Wilkins, 2022)
The aim of this study was to investigate the predictive value of PLR and NLR as an indicator of pathological complete response (pCR) in patients with breast cancer after NACT. One hundred thirty-nine patients with early ...
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
(NLM (Medline), 2023)
Atezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated the prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy ...
Survival effect of palliative radiotherapy in patients with metastatic castration-resistant prostate cancer developing oligo-progression under antiandrogen treatment
(Istanbul University, 2023)
Objective: Androgen pathway inhibitors have a significant impact on the treatment of prostate cancer. The treatment approach is controversial in patients who develop oligo-pro-gression under anti-androgen therapy. This ...
Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer
(Elsevier B.V., 2023)
Background: Non-small cell lung cancer (NSCLC) often exhibits elevated Secreted Protein Acidic and Cysteine-Rich (SPARC) expression. In this study, we investigated the impact of SPARC expression on clinicopathologic features, ...
Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer
(Taylor and Francis Ltd., 2023)
To evaluate the tumour-infiltrating lymphocyte (TIL) rates in breast tissue before and after neoadjuvant chemotherapy (NAC) and their impact on survival, eighty-four patients with locally advanced breast cancer (LABC) were ...
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
(Springer, 2024)
Background: Prostate cancer is a prevalent cancer in men worldwide, and castration-resistant prostate cancer (CRPC) is characterized by disease progression despite androgen deprivation therapy. While clinical and prognostic ...
Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes
(Taylor and Francis Ltd., 2024)
The current study was designed to assess the response to treatment, as well as clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemotherapy (NAC). From 2014 to ...